<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141659</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-385/TB-AK160108</org_study_id>
    <secondary_id>U1111-1156-6034</secondary_id>
    <nct_id>NCT02141659</nct_id>
  </id_info>
  <brief_title>This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label Study of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist in Japanese Patients With Androgen Deprivation Treatment-Naïve Nonmetastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the tolerability and safety of TAK-385 in patients with androgen deprivation
      treatment-naïve non-metastatic prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the tolerability and safety of TAK-385 in patients
      with androgen deprivation treatment-naïve non-metastatic prostate cancer. This study consists
      of two parts: Part A, multiple dose-rising phase and Part B, an expansion phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2014</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does-limiying toxicity(DLT): Does resing phase</measure>
    <time_frame>up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with markedly abnormal advers events</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with markedly abnormal clinical laboratory tests</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values, including hematology, serum chemistries, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with markedly abnormal vital signs</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Vital signs will include body temperature, sitting blood pressure, and pulse (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with markedly abnormal 12-lead electrocardiogram (ECG) parameters</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The percentage of participants who meet markedly abnormal criteria specified by the protocol and statistical analysis plan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum prostate-specific antigen (PSA)</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of TAK-385</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum testosterone concentration</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TAK-385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-385 will be taken orally every morning at least 30 minutes before the first meal of the day.
320-360mg(loading dose), 40-160mg(maintenance dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-385</intervention_name>
    <description>Drug (including placebo)</description>
    <arm_group_label>TAK-385</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patients judged by the investigator to have the capacity to understand the study
             and follow the study rules.

             2. Patients whose written consent (signature or printed name and personal seal on
             informed consent form) can be obtained before any study procedures are performed.

             3. Japanese male patients 20 or more years of age at the time of informed consent.

             4. Patients who, if they have a female partner who could become pregnant, agree to
             practice appropriate means of contraception from the time of informed consent
             throughout the entire study treatment period and for 4 months after the last dose of
             study drug.

             5. Patients in stable medical condition, including the absence of acute exacerbations
             of chronic illnesses, serious infections, or major surgery within 4 weeks (28 days)
             prior to study treatment initiation.

             6. Patients with histologically or cytologically confirmed prostate cancer. 7.
             Patients whose clinical diagnosis is T1-4 N0 M0, or Tx N0 M0 for patients who have
             undergone radical prostatectomy.

             8. Patients who are considered eligible for hormone therapy for prostate cancer.

             9. Patients who have not received hormone therapy (e.g., GnRH agonist, GnRH
             antagonist, steroidal antiandrogen, non-steroidal androgen) for prostate cancer.

             10. Patients who have not undergone surgical castration. 11. Patients with serum
             testosterone at screening &gt; 150 ng/dL. 12. Patients meeting either of the following
             criteria for PSA at screening. Untreated prostate cancer: PSA at screening &gt; 4.0 ng/mL
             Treated* prostate cancer: PSA at screening &gt; 0.2 ng/mL

             *: Patients who have undergone prostatectomy or either or both of high intensity
             focused ultrasound therapy or radiotherapy (excluding 125I-brachytherapy) prior to the
             start of this study.

             13. Eastern Cooperative Oncology Group (ECOG) Performance Status [17] of 0 or 1
             (Appendix G) 14. Body mass index (BMI*) at screening ≥ 18.0 kg/m2

        Exclusion Criteria:

          -  1. Patients exhibiting symptoms judged related to prostate cancer by the investigator
             (e.g., bone pain, pelvic pain, ureteral obstruction) who urgently require hormone
             therapy such as GnRH agonist, GnRH antagonist, or CAB/MAB therapy, chemotherapy, or
             radiotherapy.

             2. Patients who have received 5-alpha reductase inhibitors (except for patients who
             have been treated for male-pattern alopecias).

             3. Patients who have received chemotherapy for prostate cancer (including
             estramustine).

             4. Patients who have received 125I-brachytherapy. 5. Patients who received
             radiotherapy (except for 125I-brachytherapy) within 16 weeks (112 days) before study
             treatment initiation.

             6. Patients who underwent prostatectomy within 16 weeks (112 days before study
             treatment initiation.

             7. Treatment with any investigational compound within the 4 weeks (28 days) prior to
             the first dose of study drug or ongoing participation in another experimental trial
             related to the treatment of prostate cancer.

             8. Diagnosis or treatment for another systemic malignancy within 2 years before study
             treatment initiation, or who had received a diagnosis of another malignancy before
             that and have evidence of residual disease. Patients with non-melanoma skin cancer or
             carncinoma in situ who have undergone complete resection will not be excluded from the
             study.

             9. Patients taking drugs with moderate to strong CYP3A4 inhibitory or inducing
             effects, or any medications, supplements, or food products with P-gp inhibitory
             effects, in the 2 weeks (14 days) prior to study treatment initiation.

             10. Patients who have received TAK-385 in a past clinical study. 11. Patients for whom
             it would be difficult to collect blood from a peripheral vein.

             12. Patients with uncontrolled and clinically significant nervous, circulatory,
             pulmonary, hepatic, renal, metabolic, gastrointestinal, urogenital, or endocrine
             disorders, or other abnormalities (except for the targeted disease) that could affect
             study participation or the study results. Also, patients meeting any of criteria a
             through c below.

        A) Patients with uncontrolled diabetes (HbA1C &gt; 8% at screening). However, patients whose
        HbA1c is brought under control with diabetes medications may be rescreened.

        B) Patients with uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg and
        diastolic blood pressure &gt; 90 mmHg at 2 separate measurements taken no more than 60 minutes
        apart at screening). Patients whose blood pressure is brought under control by
        antihypertensive medication may be rescreened.

        C) Patients with myocardial infarction, unstable symptomatic ischemic heart disease,
        arrhythmias of CTCAE Grade &gt; 2, thromboembolism (deep vein thrombosis, pulmonary embolism,
        or symptomatic cerebrovascular events), or other heart diseases (e.g., pericardial
        effusion, restrictive cardiomyopathy). However, chronic stable atrial fibrillation
        controlled by stable anticoagulant therapy will be allowed.

        13. Patients with bilateral hydronephrosis or bladder neck outlet obstruction. 14. Known
        hypersensitivity to TAK-385, TAK-385 excipients, or GnRH antagonists. 15. Patients with a
        past history of gastrointestinal tract treatments (including gastrectomy) or
        gastrointestinal disease that could affect the drug absorption or tolerability
        (malabsorption, esophageal reflux, peptic ulcer, erosive esophagitis).

        16. Patients positive for hepatitis B surface antigens (HBsAg), hepatitis C antibodies
        (HCV), human immunodeficiency virus (HIV) antibodies, or serologic test for syphilis, or
        with life-threatening disease other than cancer, at screening.

        17. Clinically relevant ECG abnormalities, or the following ECG abnormalities, at
        screening.

          -  Q-wave infarction, unless identified 6 or more months prior to TAK-385 treatment
             initiation

          -  QTcF interval &gt; 450 msec (when calculating the QTc interval, Fridericia's equation
             [QT/RR0.33] will be used) 18. Patients with congenital QT prolongation. 19. Current
             use of Class 1A or Class 3 antiarrhythmic medications. 20. New York Heart Association
             Class III or IV heart failure. 21. Patients with clinical laboratory abnormalities
             suggesting clinically relevant underlying disease, or with any of the following
             abnormal results, at screening.

          -  Serum creatinine ≥ 2.0 mg/dL

          -  ALT or AST ≥ 1.5 x ULN for the study site

          -  Total bilirubin ≥ 2 x ULN for the study site

          -  Neutrophil count &lt; 1,500/mm3, platelet count &lt; 100,000/μL, hemoglobin &lt; 10.0 g/dL

          -  Results of heart-related tests (creatine kinase MB [CK-MB] and cardiac troponin T)
             exceeding the study sites reference value.

             22. Patients found to have clinical problems on the basis of examination findings, ECG
             findings, or chest X-ray findings at screening.

             23. Patients considered unlikely by investigators to be able to follow the study
             protocol or considered ineligible for the study by investigators for other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sakura-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2014</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

